| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5602423 | Heart, Lung and Circulation | 2017 | 9 Pages |
Abstract
Insulin is required if glucose levels are very high. Otherwise, metformin, acarbose, some GLP1 receptor agonists and one SGLT2i appear beneficial for CV outcomes.
Keywords
RRRDPP4iSGLT2GLP1MACEC-IMTDPP4HbA1cRCTPPARRandomised controlled trialMyocardial infarctionPeripheral arterial diseaseDipeptidyl peptidase-4Major adverse cardiac eventcardiovascularDPP4 inhibitorsheart failurehazard ratioglycated haemoglobinPADglucagon-like peptide 1relative risk reductionperoxisome proliferator-activated receptor
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Cecilia MBBS, Jennifer MBBS, Jenny E. MBBS, FRACP, PhD,